Collegium Pharmaceutical, Inc. (COLL) is a leading specialty pharmaceutical company, incorporated in 2003 and headquartered in Stoughton, Massachusetts, USA. The company is committed to developing and commercializing innovative pharmaceutical products to promote the management and treatment of an array of medical conditions.
The primary focus of Collegium Pharmaceutical, Inc. is on developing advanced, differentiated products for the treatment of pain. The company is known for its unique and proprietary DETERx technology platform, which is designed to provide extended-release delivery, enabling patients with difficulty swallowing to still be able to take their medication by sprinkling it onto food.
Collegium Pharmaceutical, Inc. flagship product is Xtampza ER (oxycodone), an abuse-deterrent, extended-release oral formulation of oxycodone approved by FDA. The drug aims at managing pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Its uniqueness lies in the patent-protected DETERx technology that maintains the extended-release and steady analgesic effects and its ability to resist methods of manipulation commonly associated with opioid abuse, such as chewing, crushing or dissolving.
In addition to Xtampza ER, other products in Collegium's portfolio include Nucynta ER (tapentadol extended-release tablets), a strong analgesic for controlling chronic pain in adults, and Nucynta (tapentadol), an immediate-release variant for controlling acute pain in adults.
Collegium Pharmaceutical, Inc. has remained committed to its mission to deliver top-notch pharmacotherapy in areas of high unmet medical needs, with pain management being paramount. By investing in research and innovation, the company remains at the forefront of providing ideal and overall solutions for pain mitigation. It maintains a corporate culture that prioritizes ethical behavior and accountability, fostering core values of integrity, patient focus, trust and respect, teamwork, and the pursuit of excellence.
The company is listed on the NASDAQ and caters to the medical communities within the United States. By offering innovative solutions for pain management, it continues to uphold its dedication to significantly improving the lives of people with painful conditions, ensuring its position as a leader in the development of pain management pharmaceuticals.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Collegium Pharmaceutical reported a record quarterly net revenue of $216.3 million in Q3 2026, marking a 3% year-over-year increase, primarily fueled by the strong performance of its ADHD portfolio, including Jornay PM and Azstarys. The ADHD segment now constitutes over 36% of total revenue, with Jornay PM prescriptions growing 16% year-over-year and Azstarys generating $26.5 million in its first full quarter under Collegium's ownership. The company reaffirmed its 2026 financial guidance, emphasizing continued growth in the ADHD business, sustained cash flow from its pain portfolio, and strategic capital allocation including a $50 million accelerated share repurchase program.
Collegium Pharmaceutical (NASDAQ: COLL) reported Q3 2026 revenue of $216.3 million, meeting Wall Street expectations, and full-year revenue guidance of $840 million, which is slightly above consensus estimates. The company's non-GAAP profit per share exceeded analyst expectations, leading to a 6.7% surge in stock price. Strong demand for its ADHD portfolio, particularly JORNAY PM and AZSTARYS, contributed to these positive results.